FDA Accepts Priority Review for Sevabertinib (BAY 2927088) in HER2-Mutant NSCLC
Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor (TKI), for…
Quadria Capital Closes Oversubscribed $1 Billion Fund III to Drive Healthcare Innovation in Asia
Quadria Capital, Asia’s premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target. The oversubscribed fundraise comprises over US$954 million in primary commitments…
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
Correction: MAIA Biotechnology Announces $695,000 Private Placement This is a correction of the announcement. The number of shares and expected proceeds from the private placement have been corrected to 463,332 shares and approximately $695,000. All other aspects of the announcement…
Guardant Health Unveils Nearly a Dozen Innovative Smart Liquid Biopsy Features for Guardant360 Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications…
Lyra Health Welcomes Sandra Beaver as Chief Financial Officer
Lyra Health, the leading provider of mental health solutions for employers, has named Sandra Beaver as Chief Financial Officer, effective June 16. She brings exceptional business acumen and judgement, global public company experience, and expertise in complex international operations to…
Lupin and SteinCares Sign Licensing and Supply Deal for Ranibizumab in Latin America
Global pharmaceutical company Lupin Limited has announced a licensing and supply agreement with SteinCares, a prominent specialty healthcare firm in Latin America, for the commercialization of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. Under this collaboration, SteinCares…
DAYVIGO® (Lemborexant) Approved in China for Insomnia
(Headquarters: Tokyo; CEO: Haruo Naito) announced that its in-house developed dual orexin receptor antagonist, DAYVIGO® (brand name in China: 达卫可®, generic name: lemborexant), has been approved in China for the treatment of adult patients with insomnia. This condition is characterized…
Otsuka’s Sibeprenlimab for IgAN Gets FDA Priority Review
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sibeprenlimab, an investigational monoclonal antibody developed to treat adults with immunoglobulin A nephropathy…
Shaping Tomorrow Through the Eyes of Pompe Patients
Empowering Patients Through Collaboration: Astellas’ Commitment to Pompe Disease Awareness This article shares real patient stories to raise awareness about Pompe disease. Individual experiences may differ. This content is for educational purposes only and should not be considered medical advice.…
Practice-Changing Data, Breakthrough Modalities, and China in the Spotlight at #ASCO25
Running from Friday through June 3 at McCormick Place Convention Center, the 2025 ASCO Annual Meeting promises to unveil pivotal data from a wide range of clinical trials. Experts suggest the findings could have far-reaching implications across oncology research and…
FDA Pushes Forward With Drug Import Plan as Canada Acts To Safeguard Its Supply
Health Canada has reaffirmed its commitment to safeguarding the country’s drug supply, stating it is “taking all necessary action” to ensure Canadians have continued access to essential prescription medications. This comes as the United States pushes forward with plans to…
Dr. Mark Stetter Joins Zoetis Board of Directors
Dr. Mark Stetter Joins Zoetis Board of DirectorsDean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board (NYSE: ZTS) today announced the election of Dr. Mark Stetter to…